会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • EXTRACTABILITY AND BIOAVAILABILITY OF THE NATURAL ANTIOXIDANT ASTAXANTHIN FROM A GREEN ALGA, HAEMATOCOCCUS PLUVIALIS
    • 天然抗氧化剂ASTAXANTHIN从绿色ALGA,HAEMATOCOCCUS PLUVIALIS的可提取性和生物利用度
    • WO2006107736A1
    • 2006-10-12
    • PCT/US2006/011826
    • 2006-03-31
    • ALGAEN CORPORATIONHU, QiangSOMMERFELD, Milton, R.LU, Fan
    • HU, QiangSOMMERFELD, Milton, R.LU, Fan
    • A01N61/00A01N65/00A61K31/00A61K36/00A01H13/00
    • A61K36/05A23K10/12A23K20/105A23K50/10A23K50/30A23K50/75A23K50/80A23L17/60A61K31/00
    • As the richest source of astaxanthin, a natural antioxidant and coloring agent, the unicellular green alga, Haematococcus pluvialis, is being commercially exploited. A major constraint in the Haematococcus production system, however, is the thick, rigid cell walls associated with astaxanthin-rich cysts (or aplanospores). The thick walls prevent the extraction of cellular materials and consequently reduce the bioavailability of astaxanthin. Using a physical, chemical, or enzymatic method to disrupt the cell wall has proven to be very expensive and also introduce the risk of oxidation of astaxanthin by atmospheric oxygen The present invention provides a novel method for solving this problem by introducing two genetically modified Haematococcus pluvialis mutants. These two mutants, named as D 13- 17 and N54-22, contain remarkably reduced amounts of cell wall materials, but retain the growth potential and ability to accumulate astaxanthin as high as the wild type strain. Organic solvent extraction efficiency assay has demonstrated that cellular astaxanthin can be more effectively and efficiently extracted from the cell wall-deficient mutants than from the wild type, suggesting that the mutants may provide better bioavailability of astaxanthin to humans and animals. The said mutants can be used for production of natural astaxanthin for human and animal consumption
    • 作为天然抗氧化剂和着色剂的虾青素最丰富的来源,单细胞绿藻,红球藻(Haematococcus pluvialis)正在商业上被利用。 然而,血球菌生产系统的主要制约因素是与富含虾青素的囊肿(或淀粉孢子)相关的厚而刚性的细胞壁。 厚壁防止细胞材料的提取,从而降低虾青素的生物利用度。 使用物理,化学或酶学方法破坏细胞壁已被证明是非常昂贵的,并且还引起大气氧氧化虾青素的风险本发明提供了一种通过引入两种遗传修饰的红潮球菌(Hematococcus pluvialis)来解决这个问题的新方法 突变体。 这两个突变体,命名为D 13-17和N54-22,含有显着减少量的细胞壁材料,但保留生长潜力和积累与野生型菌株一样高的虾青素的能力。 有机溶剂提取效率测定表明,从野生型中可以更有效地从细胞壁缺陷突变体提取细胞虾青素,这表明突变体可以提供更好的虾青素对人和动物的生物利用度。 所述突变体可用于生产天然虾青素用于人和动物消费